As demand soars for Eli Lilly's diabetes and obesity newcomers Mounjaro and Zepbound, the company has spent the past year pouring billions into its manufacturing operations.

Now, the company is taking its manufacturing push to Germany.

The company revealed plans to build a large plant in Alzey, Germany. The investment is expected to reach USD 2.5 billion, and the site is slated to employ up to 1,000 people, Lilly said in a release.

The site will grow Lilly's manufacturing network for injectables and support the company's efforts to meet demand for several drugs, including those in its diabetes and obesity portfolio, the company said.

Lilly said it plans to utilize automation and install high-speed manufacturing lines at the site, which will boost the company's ability to supply incretins for its diabetes and obesity offerings.

Construction on the site is set to begin next year, and the plant is expected to commence operations in 2027.